Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 293-300

  Boffa, Daniel J ^a   Luan, Fulung ^a   Thomas, Dolca ^a   Yang, Hua ^a   Sharma, Vijay K ^a   Lagman, Milagros ^a   Suthanthiran, Manikkam ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED DBA; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 1642576127     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0629-3     Document Type: Article

References (34)

1. American Cancer Society. Estimated new cancer cases and deaths for all sites, United States. In: Cancer Facts and Figures 2001. Atlanta, GA: American Cancer Society, 5-14. 2001.
2. McKean-Cowdin, R., Feigelson, H. S., Ross, R. K., Pike, M. C., and Henderson, B. E., Declining cancer rates in the 1990s. J. Clin. Oncol., 18: 2258-2268, 2000.
3. Kasiske, B. L., and Danpanich, E. Malignancies in renal transplant recipients. Transplant. Proc., 32: 1499-1500, 2000.
4. Cardillo, M., Rossini, G., Scalamogna, M., Pizzi, C., Poli, F., Piccolo, G., Porta, E., Malago, D., Taioli, E., Fiocchi, R., and Sirchia, G. North Italy Transplant Program. Tumor incidence in heart transplant patients: report of the North Italy Transplant Program Registry. Transplant. Proc., 33: 1840-1843, 2001.
5. Goldstein, D. J., Austin, J. H., Zuech, N., Williams, D. L., Stoopler, M. B., Michler, R. E., and Schulman, L. L. Carcinoma of the lung after heart transplantation. Transplantation, 62: 772-775, 1996.
6. Pham, S. M., Kormos, R. L., Landreneau, R. J., Kawai, A., Gonzalez-Cancel, I., Hardesty, R. L., Hattler, B. G., and Griffith, B. P. Solid tumors after heart transplantation: lethality of lung cancer. Ann. Thorac. Surg., 60: 1623-1626, 1995.
7. Vezina, C., Kudelski, A., and Sehgal, S. N., Rapamycin (AY-22, 989), a new antifungal antibiotic. 1. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot., (Tokyo), 28: 721-726, 1975.
8. Marte, R. R., Klicius, J., and Galet, S., Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol., 55: 48-51, 1997.
9. Eng, C. P., Sehgal, S. N., and Vezina, C., Activity of rapamycin (AY-22. 989) against transplanted tumors. J. Antibiot., (Tokyo). 37: 1231-1237, 1984.
10. Ingle, G. R., Sievers, T. M., and Holt, C. D., Sirolimus: continuing the evolution of transplant immunosuppression. Ann. Pharmacother. 34: 1044-1055, 2000.
11. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 78: 35-43, 1994.
12. 1-arresting rapamycin-receptor complex. Nature (Lond.), 369: 756-758, 1994.
13. Lorenz, M. C., and Heitman, J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J. Biol. Chem., 270: 27531-27537, 1995.
14. Blume-Jensen, P., and Hunter, T. Oncogenic kinase signalling. Nature (Lond.), 411: 355-365, 2001.
15. Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q. P., Kasuga, M., Nishimoto, I., and Avruch, J. Regulation of elF-4E BP1 phosphorylation by mTOR. J. Biol. Chem., 272: 26457-26463, 1997.
16. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Wash. DC), 257: 973-977, 1992
17. Nettesheim, P., and Hammons, A. S., Induction of squamous cell carcinoma in the respiratory tract of mice. J. Natl. Cancer Inst. (Bethesda), 47: 697-701, 1971.
18. Hale, D. A., Gottschalk, R., Fukuzaki, T., Wood, M. L., Maki, T., and Monaco, A. P. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation, 63: 359-364, 1997.
19. Hale, D. A., Gottschalk, R., Maki, T., and Monaco, A. P. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation, 64: 897-900, 1997.
20. Chen, H., Qi, S., Xu, D., Vu, D. M., Fitzsimmons, W. E., Bekersky, I., Peets, J., Sehgal, S. N., and Daloze, P. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant. Proc., 30: 1039-1041, 1998.
21. Kaneko, T., and LePage, G. A. Growth characteristics and drug responses of a murine lung carcinoma in vitro and in vivo. Cancer Res., 38: 2084-2090, 1978.
22. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.
23. Mahalati, K., and Kahan, B. D., Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet., 40: 573-585, 2001.
24. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., and Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8: 128-135, 2002.
25. Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., and Suthanthiran, M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (Lond.), 397: 530-534, 1999.
26. Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., and Suthanthiran, M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int., 63: 917-926, 2003.
27. Shi, Y., Gera, J., Hu, L., Hsu, J. H., Bookstein, R., Li, W., and Lichtenstein, A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res., 62: 5027-5034, 2002
28. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., and Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice. Proc. Natl. Acad. Sci. USA, 98: 10320-10325, 2001.
29. Chen, Y., Zheng, Y., and Foster, D. A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene, 22: 3937-3942, 2003.
30. Rinaldi, M., Pellegrini, C., D'Armini, A. M., Aiello, M., Negri, M., Arbustini, E., Ippoliti, G., and Vigano, M. Neoplastic disease after heart transplantation: single center experience. Eur. J. Cardiothorac. Surg., 19: 696-701, 2001.
31. Kris, M. G., and Azzoli, C. G., Chemotherapy for early stage non-small cell lung cancer. Lung Cancer, 34 (Suppl 3): S49-S52.
32. Sorenson, S., Glimelius, B., and Nygren, P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol., 40: 327-339, 2001.
33. Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., and Suthanthiran, M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation, 73: 1565-1572, 2002.
34. Hidalgo, M., and Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19: 6680-6686, 2000.